Jupiter Wellness Announces First Patient Dosing fo
Post# of 104
JUPITER, FL / ACCESSWIRE / October 19, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing a cannabinoid receptor agonist for the treatment of first degree burns, announced the enrollment and dosing of the first patient in the study.
The double-blinded placebo-controlled study will enroll 50 patients with newly diagnosed first degree burns of superficial partial thickness on 10% or less of the patient's total body surface area. The primary endpoint is time to full re-epithelialization of the wound. This is an investigational international study with a protocol similar to a US FDA Phase I study.
"Jupiter Wellness is committed to the treatment of skin diseases through the development and commercialization of our, patent pending, proprietary skincare products" stated Jupiter CEO Brian John. "The treatment of burns is an important indication that complements and extends our product lines including CaniSun™ and Photocil™. We look forward to announcing our results by the end of December and being able to register our second OTC product with the FDA and begin to help people with burns all over the world."
The burn care market was valued at $2.1 billion in 2020 and is expected to grow at a CAGR of 7% from 2021 to 2028 driven by rising incidence of burns, favorable reimbursement policies, and technological advancement.
About Jupiter Wellness
Jupiter Wellness, Inc. (NASDAQ:JUPW) is a leading developer of skincare therapeutics and treatments. The Company's product pipeline of enhanced skincare therapeutics focuses on the endocannabinoid system to address indications including psoriasis, eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenue from a growing line of proprietary over-the-counter skincare products including its CaniSun™ sunscreen and other wellness brands sold through www.cbdcaring.com.
For additional information, please visit www.jupiterwellness.com. The Company's public filings can be found at www.Sec.gov.
Safe Harbor Statement
To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the "Company"

Investor & Public Relations Contact Info
Phone: 561-462-2700
Email: info@JupiterWellness.com
SOURCE: Jupiter Wellness, Inc.
View source version on accesswire.com:
https://www.accesswire.com/668602/Jupiter-Wel...gree-Burns

